Atossa Therapeutics
ATOS
17 hedge funds and large institutions have $501K invested in Atossa Therapeutics in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
42% more funds holding
Funds holding: 12 → 17 (+5)
35% less capital invested
Capital invested by funds: $775K → $501K (-$274K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$181K |
| 2 |
Renaissance Technologies
New York
|
+$63.1K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$20K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$16.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Concert Wealth Management
San Jose,
California
|
-$55K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$13.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.54K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
ATOS Hedge Fund Activity: Q4 2015 in Review
17 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2015, worth a combined $501K — down 35% from $775K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATOS positions and 1 closed out — a net gain of 5 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $181K. The largest seller was Concert Wealth Management, exiting entirely with an estimated $55K sold.
- 17 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2015, up from 12 in Q3 2015.
- Funds reported $501K of Atossa Therapeutics stock for Q4 2015, down 35% quarter-over-quarter.
- 6 funds opened new Atossa Therapeutics positions in Q4 2015 and 1 closed out, a net change of +5 holders.
- The largest Atossa Therapeutics buyer in Q4 2015 was Anson Funds Management, an estimated $181K added.
- The largest Atossa Therapeutics seller in Q4 2015 was Concert Wealth Management, an estimated $55K sold.
Based on aggregated 13F filings for Q4 2015.